Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management. 

The news comes after Veranova recently announced expansion – estimated at $30 million – of its antibody-drug conjugate (ADC) and highly potent compound development and manufacturing capabilities.

A seasoned commercial and business executive, Cécile brings a deep understanding of contract development and manufacturing organizations (CDMO) and the pharmaceutical industry. Her proven track record of building teams and transforming organizations and extensive experience across multiple drug modalities will ensure Cécile is an integral part of Veranova’s continued growth.

“I’m delighted to have Cécile join the Veranova team as our Chief Commercial Officer” said Mike Riley, Chief Executive Officer of Veranova. “Her expertise and track record in building and growing businesses will be invaluable as Veranova continues to execute our strategy to build a world-class CDMO.”